BR0316020A - Composto, composição farmacêutica, uso de um composto, e, método para tratar um distúrbio - Google Patents

Composto, composição farmacêutica, uso de um composto, e, método para tratar um distúrbio

Info

Publication number
BR0316020A
BR0316020A BR0316020-3A BR0316020A BR0316020A BR 0316020 A BR0316020 A BR 0316020A BR 0316020 A BR0316020 A BR 0316020A BR 0316020 A BR0316020 A BR 0316020A
Authority
BR
Brazil
Prior art keywords
alkyl
alkoxy
halogen
optionally substituted
compound
Prior art date
Application number
BR0316020-3A
Other languages
English (en)
Inventor
Pedro Harold Han Hermkens
Herman Thijs Stock
Neeltje Miranda Teerhuis
Johannes Petrus Maria Lommerse
Jaap Van Der Louw
Original Assignee
Akzo Nobel Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akzo Nobel Nv filed Critical Akzo Nobel Nv
Publication of BR0316020A publication Critical patent/BR0316020A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Abstract

"COMPOSTO, COMPOSIçãO FARMACêUTICA,USO DE UM COMPOSTO, E, MéTODO PARA TRATAR UM DISTúRBIO". Esta invenção fornece compostos não esteróides com afinidade para o receptor de androgênio e utilidade para tratamentos relacionados ao receptor de androgênio, tendo uma estrutura de acordo com a fórmula (1), em que X é S, SO OU S0~ 2~; R¬ 1¬ é uma estrutura monocíclica, hetero- ou homocíclica, saturada ou insaturada, de anel de 5 ou 6 membros, opcionalmente substituída com um ou mais substituintes selecionados do grupo consistindo de halogênio, CN, fluoroalquila (C1 -C4), nitro, alquila (C1C4), alcóxi (C1 -C4) ou fluoroalcóxi (C1 -C4); R¬ 2¬ é 2-nitrofenila, 2cianofenila, 2-hidroximetil-fenila, piridin-2-ila, piridin-2-il-N-óxido, 2benzamida, éster metílico de ácido 2-benzóico ou 2-metoxifenila; R¬ 3¬ é H, halogênio ou alquila (C1 -C4); R¬ 4¬ é H, OH, alcóxi (C1 -C4) ou halogênio; R¬ 5¬ é H, OH, alcóxi (C1-C4), NH~ 2~, CN, halogênio, fluoroalquila (C1-C4), NO~ 2~, hidroxialquila (C1 -C4), C0~ 2~H, C0~ 2~alquila C1 -C6, OU R¬ 5¬ é NHR¬ 6¬, em que R¬ 6¬ é acila C1-C6 opcionalmente substituída com um ou mais halogênios, S(O)~ 2~alquila (C1-C4) OU S(0)~ 2~arila opcionalmente substituída com alquila (C1 -C4) ou um ou mais halogênios, ou R¬ 5¬ é C(O)N(R¬ 8¬,R¬ 9¬), em que R¬ 8¬ e R¬ 9¬, cada um independentemente, são H, cicloalquila C~ 3~-C~ 6~, ou CH~ 2~R¬ 1¬O, em que R¬ 1¬O é H, alquila C~ 1~-C~ 5~, alquenila C~ 1~-C~ 5~, hidroxialquila C~ 1~-C~ 3~, alquiléster (C1C4) de carboxialquila (C1-C4), alcóxi C~ 1~-C~ 3~-alquila C~ 1~-C~ 3~, (mono- ou dialquila (C1 -C4))aminometila, (mono- ou dialquila (C1 -C4))aminocarbonila, ou um anel monociclico, homo- ou heterocíclico, aromático ou não aromático de 3, 4, 5 ou 6 membros, ou R¬ 8¬ e R¬ 9¬ formam, juntos com o N um anel heterocíclico saturado ou insaturado, opcionalmente substituído com alquila (C1 -C4) de 5 ou 6 membros; ou uma sua forma de sal ou hidrato.
BR0316020-3A 2002-11-07 2003-11-03 Composto, composição farmacêutica, uso de um composto, e, método para tratar um distúrbio BR0316020A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US42457902P 2002-11-07 2002-11-07
EP02079648 2002-11-07
PCT/EP2003/050783 WO2004041782A1 (en) 2002-11-07 2003-11-03 Indoles useful in the treatment of androgen-receptor related diseases

Publications (1)

Publication Number Publication Date
BR0316020A true BR0316020A (pt) 2005-09-20

Family

ID=42635437

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0316020-3A BR0316020A (pt) 2002-11-07 2003-11-03 Composto, composição farmacêutica, uso de um composto, e, método para tratar um distúrbio

Country Status (15)

Country Link
EP (1) EP1585727B1 (pt)
JP (1) JP4643989B2 (pt)
CN (1) CN100391944C (pt)
AT (1) ATE469128T1 (pt)
AU (1) AU2003301853B2 (pt)
BR (1) BR0316020A (pt)
CA (1) CA2504907C (pt)
ES (1) ES2344836T3 (pt)
NZ (1) NZ539657A (pt)
PL (1) PL376728A1 (pt)
RS (1) RS20050340A (pt)
RU (1) RU2328484C2 (pt)
TW (1) TWI310032B (pt)
UA (1) UA79504C2 (pt)
WO (1) WO2004041782A1 (pt)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200602317A (en) 2004-04-23 2006-01-16 Akzo Nobel Nv Novel androgens
DE102004047272A1 (de) * 2004-09-24 2006-04-06 Schering Ag Inhibitoren der löslichen Adenylatzyklase
DE102005027274A1 (de) * 2005-06-08 2006-12-14 Schering Ag Inhibitoren der löslichen Adenylatzyklase
US7417066B2 (en) 2005-06-08 2008-08-26 Schering Ag Inhibitors of soluble adenylate cyclase
CN101203491A (zh) * 2005-06-24 2008-06-18 伊莱利利公司 可用作雄激素受体调节剂的四氢咔唑衍生物（sarm）
WO2007073231A1 (fr) * 2005-12-23 2007-06-28 Victor Lvovoch Limonov Agent pour traiter des maladies tumorales, procede de fabrication correspondant et procede pour traiter des maladies tumorales
DE102006014324B4 (de) * 2006-03-23 2009-01-08 Bayer Schering Pharma Aktiengesellschaft Inhibitoren der löslichen Adenylatzyklase
EP3412290B1 (en) 2006-03-27 2021-03-03 The Regents of The University of California Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases
EP2079466B1 (en) * 2006-09-29 2014-01-15 GlaxoSmithKline LLC Substituted indole compounds
US8268872B2 (en) 2008-02-22 2012-09-18 Radius Health, Inc. Selective androgen receptor modulators
ES2488990T3 (es) 2008-02-22 2014-09-01 Radius Health, Inc. Moduladores selectivos del receptor de andrógenos
EP2531029B1 (en) 2010-02-04 2016-10-19 Radius Health, Inc. Selective androgen receptor modulators
WO2011143469A1 (en) 2010-05-12 2011-11-17 Radius Health,Inc Therapeutic regimens
US8642632B2 (en) 2010-07-02 2014-02-04 Radius Health, Inc. Selective androgen receptor modulators
WO2012047617A1 (en) 2010-09-28 2012-04-12 Radius Health, Inc. Selective androgen receptor modulators
EP3834824A1 (en) 2014-03-28 2021-06-16 Duke University Method of treating cancer using selective estrogen receptor modulators
US9421264B2 (en) 2014-03-28 2016-08-23 Duke University Method of treating cancer using selective estrogen receptor modulators
WO2017223115A1 (en) 2016-06-22 2017-12-28 Radius Health, Inc. Ar+ breast cancer treatment methods
JP7481115B2 (ja) 2017-01-05 2024-05-10 ラジウス ファーマシューティカルズ，インコーポレイテッド Ｒａｄ１９０１－２ｈｃｌの多形性形態
CN113861186B (zh) * 2021-09-10 2023-08-25 浙江师范大学 基于异恶唑取代苯甲酰胺类衍生物及抗***癌药物应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ179580A (en) * 1974-12-30 1978-04-03 Mcneilab Inc 2-or 3-(w-tertiaryaminoalkyl)-thioindoles and the corresponding sulfinyl and sulfonyl analogs
US4059583A (en) * 1975-11-13 1977-11-22 Mcneil Laboratories, Incorporated Substituted indoles
GB9204365D0 (en) * 1992-02-28 1992-04-08 Pfizer Ltd Indoles
RU2337909C2 (ru) * 2002-02-01 2008-11-10 Ф.Хоффманн-Ля Рош Аг Замещенные индолы и фармацевтическая композиция, обладающая агонистической активностью в отношении альфа-1a/l адренорецептора
TW200401641A (en) * 2002-07-18 2004-02-01 Wyeth Corp 1-Heterocyclylalkyl-3-sulfonylindole or-indazole derivatives as 5-hydroxytryptamine-6 ligands

Also Published As

Publication number Publication date
CA2504907C (en) 2011-10-11
ATE469128T1 (de) 2010-06-15
WO2004041782A1 (en) 2004-05-21
CA2504907A1 (en) 2004-05-21
RU2328484C2 (ru) 2008-07-10
CN1714078A (zh) 2005-12-28
JP2006507293A (ja) 2006-03-02
PL376728A1 (pl) 2006-01-09
RS20050340A (en) 2007-06-04
NZ539657A (en) 2008-04-30
EP1585727B1 (en) 2010-05-26
AU2003301853B2 (en) 2010-02-18
EP1585727A1 (en) 2005-10-19
UA79504C2 (en) 2007-06-25
TW200418793A (en) 2004-10-01
AU2003301853A1 (en) 2004-06-07
ES2344836T3 (es) 2010-09-08
JP4643989B2 (ja) 2011-03-02
TWI310032B (en) 2009-05-21
CN100391944C (zh) 2008-06-04
RU2005117374A (ru) 2006-01-20

Similar Documents

Publication Publication Date Title
BR0316020A (pt) Composto, composição farmacêutica, uso de um composto, e, método para tratar um distúrbio
RS50918B (sr) Novi estri fluorenkarbonske kiseline, postupak za njihovo pripremanje, kao i njihova upotreba kao lekova
AR054021A1 (es) Derivados de ciclopentapiridina y tetrahidroquinolina
BRPI0413233A (pt) novos compostos
ES2191484T3 (es) Compuestos heterociclicos como inhibidores de enzimas de rotamasa.
RS51044B (sr) 2-(piridin-2-ilamino)-pirido(2,3-d)pirimidin-7-oni
WO2007149448A3 (en) Pyrazinones as cellular proliferation inhibitors
EA200602170A1 (ru) Производные пиперидина, композиции на их основе, способы их применения
MX9204139A (es) Nuevos derivados de bencimidazolona, procedimiento para su preparacion y composicion farmaceutica que los contiene.
ATE266636T1 (de) Benzimidazolinone, benzoxazolinone, benzopiperazinone, indanone und deren derivate als faktor xa inhibitoren
RS52715B (en) HYDROXYBENZAMIDE DERIVATIVES AND THEIR APPLICATIONS AS HSP90 INHIBITORS
BR0316146A (pt) Derivados de amida do ácido 3-(2-hidróxifenil)-1h-pirazol-4-carboxìlico como inibidores de hsp90 para o tratamento de câncer
ATE292628T1 (de) Chinazolinderivate
AR064521A1 (es) Activador de glucoquinasa
MX2010000658A (es) Derivados de pirimidina 934.
UA81561C2 (en) Use of n-arylhydrazine derivative and method for controlling non-crop pests
ME00108B (me) DE RIVATI DIOKSAN-2-ALKILKARBAMATA, POSTUPAK ZA NJIHOVO DOBIJANJ E l PRIMENA ISTIH U TERAPEUTICIMA
DE60014393D1 (de) Aminobenzophenone als inhibitoren von il-1beta und tnf-alpha
BRPI0408353A (pt) composto, composição farmacêutica, métodos para o tratamento de neoplasias suscetìveis e para o tratamento de infecções virais, e, uso de um composto
AR042706A1 (es) Compuestos (2-carboxamido)(3-amino) tiofenos y su uso para el tratamiento del cancer
PE20011008A1 (es) Derivados de pirimidina como inhibidores de ciclooxigenasa 2
KR970707107A (ko) 산화질소 합성효소 억제제로서 유용한 아미노테트라졸 유도체(aminotetrazole derivatives useful as nitric oxide synthase inhibtors)
TW200609218A (en) Bicyclic compounds
BRPI0408160B1 (pt) Processo para o preparo de ésteres do ácido nicotínico substituído e intermediários de enamina para uso nesse processo
HUP0000935A2 (hu) 3-Heteroaril-4(3H)-kinazolinon-származékok atropizomerjei és neurodegeneratív és központi idegrendszeri sérülésekkel kapcsolatos állapotok kezelésére történő alkalmazásuk

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: N.V. ORGANON (NL)

Free format text: TRANSFERIDO DE: AKZO NOBEL N.V.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 10A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2259 DE 22/04/2014.